GSK
GlaxoSmithKline PLC ADR
NYSE: GSK · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$50.38
-1.02% today
Updated 2026-05-05
Market cap
$102.18B
P/E ratio
13.43
P/S ratio
3.12x
EPS (TTM)
$3.79
Dividend yield
3.49%
52W range
$34 – $61
Volume
4.6M
WallStSmart proprietary scores
66
out of 100
Grade: B
Buy
Investment rating
4.7
Growth
C4.0
Quality
C9.0
Profitability
A+7.3
Valuation
B+5/9
Piotroski F-Score
Moderate
1.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →198 stocks currently score above 75
Price targets
Analyst target
$57.65
+14.43%
12-Month target
$67.43
+33.84%
Intrinsic (DCF)
$56.73
Margin of safety
-3.10%
0 Strong Buy1 Buy6 Hold1 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ ROE 40.90% — strong efficiency
+ Free cash flow $698.00M — positive
Risks
- Altman Z 1.26 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $29.32B | $30.33B | $31.38B | $32.67B | $32.78B | $47.8B |
| Net income | $14.96B | $4.93B | $2.58B | $5.72B | $1.74B | — |
| EPS | — | — | — | — | $3.79 | $2.57 |
| Free cash flow | $5.14B | $6.26B | $3.57B | $5.82B | $698.00M | — |
| Profit margin | 51.00% | 16.25% | 8.21% | 17.50% | 17.80% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-12-11 | GSK, PLC | Buy | 1,470,000 | $19.00 |
| 2024-09-27 | GSK, PLC | Buy | 2,791,930 | $8.00 |
| 2023-12-07 | GSK, PLC | Buy | 3,300,000 | $5.00 |
Peer comparison
Smart narrative
GlaxoSmithKline PLC ADR trades at $50.38. representing a P/E of 13.43x trailing earnings. Our Smart Value Score of 66/100 indicates the stock is good. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 1.26, it sits in the distress. TTM revenue stands at $32.78B. with profit margins at 17.80%. Our DCF model estimates intrinsic value at $56.73.
Frequently asked questions
What is GlaxoSmithKline PLC ADR's stock price?
GlaxoSmithKline PLC ADR (GSK) trades at $50.38.
Is GlaxoSmithKline PLC ADR overvalued?
Smart Value Score 66/100 (Grade B, Buy). DCF value $56.73.
What is the price target of GlaxoSmithKline PLC ADR (GSK)?
The analyst target price is $57.65, representing +14.4% upside from the current price of $50.38.
What is the intrinsic value of GlaxoSmithKline PLC ADR (GSK)?
Based on our DCF model, intrinsic value is $56.73, a -3.1% margin of safety versus $50.38.
What is the future stock price of GSK by 2030?
Our research-backed model estimates GlaxoSmithKline PLC ADR could reach $362.82 by 2030, based on analyst consensus, management guidance, and sector analysis.
What is GlaxoSmithKline PLC ADR's revenue?
TTM revenue is $32.78B.
Piotroski F-Score?
5/9 — moderate financial health.
Altman Z-Score?
1.26 — distress.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio3.12x
ROE40.90%
Beta0.30
50D MA$55.51
200D MA$48.07
Shares out2.01B
Float3.89B
Short ratio—
Avg volume4.6M
Performance
1 week-1.98%
1 month-10.63%
3 months-11.97%
YTD+2.73%
1 year—
3 years—
5 years—